Takeda has made an equity investment in new strategic partner Ovid Therapeutics as part of a round sized at $25.9m, according to a securities filing.

Ovid Therapeutics, a US-based developer of treatments for neurological diseases, has raised approximately $25.9m in equity funding from investors including pharmaceutical company Takeda, according to a regulatory filing.

Founded in 2014, Ovid is working on therapies for rare neurological diseases. Its lead product candidate, currently known as OV101, is being developed to combat symptoms of Angelman syndrome and Fragile X syndrome.

The filing did not list Takeda as an investor but it followed an announcement last week that Takeda had…